Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Furuno Sign Microarray Synthesizer Development Deal

NEW YORK, Aug. 9 (GenomeWeb News) - CombiMatrix said today that it has entered into a multi-year strategic alliance with Furuno Electric to design, engineer, and build CombiMatrix's Bench-Top DNA Microarray Synthesizer for its CustomArray microarrays.


Under the deal, Hyogo, Japan-based Furuno will pay CombiMatrix an initial fee of $1 million, as well as development and milestones payments. CombiMatrix and Furuno will co-develop a commercial Bench-Top Synthesizer instrument that will synthesize DNA microarrays at core facilities, pharmaceutical and biotech research sites, and academic microarray centers, said CombiMatrix.


Additional terms of the arrangement were not disclosed.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.